TABLE 1.
Characterization of the A. baumannii clinical isolate panel used in this studya
| Strain designation | Strain isolation |
MLST | MIC (μg/ml) of drug: |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Country | Yr | GENT | MERO | CIP | TZP | CTX | SXT | SAM | TET | ||
| ATCC 17978 | France | 1951 | 77 | 2 | 0.5 | 1 | 8/4 | 16 | >8/152 | 4/2 | 2 |
| BV94 | USA | 2011 | 2 | >128 | 32 | 256 | >256/4 | >256 | >8/152 | 16/8 | 32 |
| BV95 | Colombia | 2010 | 25 | 1 | 64 | 128 | 256/4 | 32 | >8/152 | 16/8 | >256 |
| BV172 | Israel | 2012 | 2 | >128 | 64 | 32 | 256/4 | >256 | >8/152 | 64/32 | >256 |
| BV173 | Greece | 2012 | 2 | >128 | >64 | 128 | >256/4 | >256 | >8/152 | 128/64 | >256 |
| BV174 | USA | 2012 | 2 | 8 | 64 | 256 | 256/4 | 256 | >8/152 | 32/16 | 32 |
| BV175 | Turkey | 2012 | 2 | 128 | 32 | 256 | >256/4 | 256 | >8/152 | 32/16 | 256 |
| BV185 | Mexico | 2013 | 2 | >128 | >64 | 128 | >256/4 | >256 | >8/152 | 64/32 | 256 |
| BV186 | USA | 2013 | 2 | 16 | 64 | 256 | >256/4 | >256 | >8/152 | 32/16 | 8 |
| BV187 | USA | 2013 | 2 | 32 | 64 | 256 | >256/4 | >256 | >8/152 | 16/8 | 8 |
| BV189 | Spain | 2013 | 2 | 128 | 32 | 128 | >256/4 | 256 | >8/152 | 32/16 | 16 |
| BV190 | Greece | 2012 | 1 | >128 | 64 | 64 | >256/4 | >256 | >8/152 | 64/32 | 256 |
| BV191 | China | 2013 | 2 | >128 | >64 | 256 | >256/4 | >256 | >8/152 | 128/64 | >256 |
| ATCC 25922 (quality control) | 1 | <0.06 | <0.25 | 4/4 | <0.25 | 0.125/2.34 | 4/2 | 2 | |||
a
Abbreviations: CIP, ciprofloxacin; CTX, cefotaxime; GENT, gentamicin; MERO, meropenem; MLST, multilocus sequence type; SAM, ampicillin-sulbactam; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; TZP, piperacillin-tazobactam. Classification of antibiotic resistance was done according to breakpoints published by the Clinical and Laboratory Standards Institute: susceptible (italics), intermediate (underlined), and resistant (bold) (34).